GSK2292767   Click here for help

GtoPdb Ligand ID: 10633

Synonyms: compound 2 [PMID: 30532965] | compound 3 [PMID: 26301626] | GSK-2292767
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GSK2292767 is a selective PI3Kδ inhibitor that was developed as a back-up compound to clinical lead nemiralisib (GSK2269557) [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 143.85
Molecular weight 512.18
XLogP 2.78
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1ncc(cc1NS(=O)(=O)C)c1cc(c2ncc(o2)CN2CC(C)OC(C2)C)c2c(c1)[nH]nc2
Isomeric SMILES COc1ncc(cc1NS(=O)(=O)C)c1cc(c2ncc(o2)CN2C[C@H](C)O[C@@H](C2)C)c2c(c1)[nH]nc2
InChI InChI=1S/C24H28N6O5S/c1-14-11-30(12-15(2)34-14)13-18-9-26-23(35-18)19-5-16(6-21-20(19)10-27-28-21)17-7-22(29-36(4,31)32)24(33-3)25-8-17/h5-10,14-15,29H,11-13H2,1-4H3,(H,27,28)/t14-,15+
No information available.
Summary of Clinical Use Click here for help
GSK2292767 was progressed to Phase 1 evaluation (NCT03045887) with the intended indication being asthma. In early 2020 GSK opted to terminate GSK2292767 development in respiratory diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03045887 Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes Phase 1 Interventional GlaxoSmithKline